Bottom line
PRHSX vs FSPHX: the short answer
PRHSX (T. Rowe Price Health Sciences Fund, Inc.) and FSPHX (Health Care Portfolio) share a meaningful slice of their top holdings — about 49% by weight.
FSPHX is cheaper at 0.62% vs 0.83% — a difference of $21 a year per $10,000 invested.
Over five years, PRHSX returned +4.2% a year vs +4.0% for FSPHX (reporting dates differ).
Updated Nov 19, 2026
PRHSX vs FSPHX side by side
| PRHSX | FSPHX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | T. Rowe Price | Fidelity |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.83% | 0.62% |
| Annual cost per $10k | $83 | $62 |
| 10-yr cost on $10k (prospectus) | $1,025 | $774 |
| Max front load | — | — |
| 12b-1 fee | — | 0% |
| 1-yr return | +17.7% | +14.4% |
| 5-yr return (annualized) | +4.2% | +4.0% |
| 10-yr return (annualized) | +9.1% | +9.0% |
| Best quarter | +23.5% | +22.2% |
| Worst quarter | −15.8% | −15.0% |
| Net assets (fund) | $11.9B | $5.8B |
| Number of holdings | 279 | 152 |
| Portfolio turnover | 62% | 69% |
| Returns as of | Dec 31, 2025 | Apr 30, 2026 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | PRHSX | FSPHX | Difference |
|---|---|---|---|
| 2025 | +17.7% | +14.4% | +3.3% |
| 2024 | +1.8% | +4.9% | −3.1% |
| 2023 | +3.1% | +4.1% | −1.1% |
| 2022 | −12.2% | −12.8% | +0.6% |
| 2021 | +13.3% | +11.5% | +1.8% |
| 2020 | +30.1% | +24.4% | +5.7% |
| 2019 | +29.1% | +31.5% | −2.3% |
| 2018 | +1.2% | +7.4% | −6.2% |
| 2017 | +28.0% | +24.0% | +3.9% |
| 2016 | −10.4% | −10.7% | +0.3% |
Source: Fund prospectus bar charts
Holdings overlap
12 of PRHSX's top 25 holdings also appear in FSPHX's top 25.
| Holding | PRHSX | FSPHX |
|---|---|---|
| Eli Lilly & Co | 14.28% | 8.03% |
| Johnson & Johnson | 6.63% | 4.91% |
| Unitedhealth Group Inc | 5.99% | 3.49% |
| Abbvie Inc | 5.10% | 2.03% |
| Merck & Co. Inc. | 4.01% | 1.60% |
| Gilead Sciences Inc | 2.82% | 2.21% |
| Thermo Fisher Scientific Inc | 2.52% | 4.33% |
| Natera Inc | 1.44% | 1.27% |
| Danaher Corp | 1.43% | 6.89% |
| Cvs Health Corp | 0.94% | 1.29% |
| Moderna Therapeutics Inc | 0.83% | 1.18% |
| Brightspring Health Services | 0.82% | 1.23% |
Source: SEC Form N-PORT
PRHSX top 10
- Eli Lilly & Co — 14.28%
- Johnson & Johnson — 6.63%
- Unitedhealth Group Inc — 5.99%
- Abbvie Inc — 5.10%
- Merck & Co. Inc. — 4.01%
- Gilead Sciences Inc — 2.82%
- Thermo Fisher Scientific Inc — 2.52%
- Vertex Pharmaceuticals Inc — 2.28%
- Bristol-myers Squibb Co — 2.11%
- Abbott Laboratories — 1.89%
FSPHX top 10
- ELI LILLY and CO — 8.03%
- Danaher Corp — 6.89%
- JOHNSON and JOHNSON — 4.91%
- Thermo Fisher Scientific Inc — 4.33%
- Unitedhealth Group Inc — 3.49%
- Alnylam Pharmaceuticals Inc — 2.40%
- Gilead Sciences Inc — 2.21%
- Boston Scientific Corp — 2.17%
- Ascendis Pharma A/s — 2.17%
- Fidelity Revere Street Trust — 2.17%
FAQ
What is the difference between PRHSX and FSPHX?
Which is cheaper, PRHSX or FSPHX?
Should I own both PRHSX and FSPHX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.